CPHI China 2026, one of the world's most influential pharmaceutical industry events, recently concluded in Shanghai. Hangzhou SoliPharma Co., Ltd. (“SoliPharma”) showcased its core technology platforms, specialized R&D services, and latest product pipeline at the event, engaging in in-depth discussions with partners from China and abroad as part of its ongoing global strategic expansion.
International-Standard Production Lines, Differentiated Pipeline, and Global Commercialization
SoliPharma has built its R&D and manufacturing system to high international standards, rigorously complying with cGMP requirements in China, the United States, and Europe. The company has successfully passed audits from internationally renowned pharmaceutical companies including Sandoz and Adalvo, and has established a full quality-control chain spanning from R&D through to commercial-scale production. By coordinating resources on a global scale, SoliPharma delivers high-quality, clinically valuable pharmaceutical products to international markets. At this year's event, the company unveiled the latest progress in its topical pipeline, with a focus on acne, androgenetic alopecia, eczema, and atopic dermatitis. Backed by its high-standard international production lines and globally oriented pipeline planning, SoliPharma demonstrated strong commercialization capabilities, with its quality products earning the trust of numerous partners both in China and overseas.
Deepening Core Technology Capabilities to Build Specialized CXO Services
Leveraging a mature R&D platform and a specialized technical team, SoliPharma has built differentiated, highly specialized core competitive strengths in drug polymorphism research, poorly soluble drug formulation, and topical formulation development. The company is committed to providing clients with efficient, precise, one-stop customized CXO technical services that directly address key pain points in drug development — including crystal form screening, poor drug solubility, and process optimization — helping partners reduce costs, improve efficiency, and accelerate the translation of results into outcomes.
Committed to Our Mission, Driven by Innovation
SoliPharma has consistently upheld its mission in Innovation for Better Skin Health, driving sustained investment in the field of dermatological health. The company continues to iterate and optimize its precision drug-delivery technologies, further strengthening its core technological barriers.
Looking ahead, SoliPharma will continue to refine its R&D system, accelerate its global industrial footprint, and enrich its drug development pipeline. The company is committed to leveraging its core technologies as a bridge to empower industry partners across the board, deepen industrial cooperation both domestically and internationally, and work together to embark on a new chapter of innovation in dermatological healthcare.
